<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Nichols, Emma Hitt</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Yoshida, Kazuhiro</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Sequential Therapy Fails to Extend DFS in Gastric Cancer</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2013</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2013-07-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">20-21</style></pages><abstract><style  face="normal" font="default" size="100%">There was no significant difference in 3-year disease-free survival in sequential treatment of paclitaxel and the oral fluoropyrimidine tegafur-uracil or paclitaxel and another fluoropyrimidine, S-1, in serosa-invading gastric cancer. This article presents data from the Adjuvant Paclitaxel Followed by Oral Fluorinated Pyrimidines for Locally Advanced Gastric Cancer trial [SAMIT; Yoshida K et al. J Clin Oncol 2013 (suppl; abstr LBA4002)].</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">13</style></volume></record></records></xml>